FON-2021-0886 Supplementary Data

Supplemental Figure 1. Real-world outcomes of second novel hormonal therapy or radium-223 following first novel hormonal therapy for mCRPC Kaplan–Meier curves of time to first SSE after the start of second-line therapy. (A) Radium-223 cohort. (B) Alternative NHT cohort. CI, Confidence interval; NE, Not estimable; NHT, Novel hormonal therapy; SSE, Symptomatic skeletal event.补充图1。转移性去势抵抗性前列腺癌（mCRPC）患者经首次新型内分泌治疗（NHT）后，采用二线新型内分泌治疗或镭-223治疗的真实世界结局：二线治疗启动后至首次症状性骨骼事件（SSE）发生时间的Kaplan-Meier曲线。 （A）镭-223队列；（B）替代性新型内分泌治疗队列。 缩写说明：CI为置信区间（Confidence interval）；NE为不可估计（Not estimable）；NHT为新型内分泌治疗（Novel hormonal therapy）；SSE为症状性骨骼事件（Symptomatic skeletal event）。